Retinal Degeneration clinical trials
The registry lists 132 studies for Retinal Degeneration across more than 10 countries. 23 are recruiting or about to start. 24 of them are mainly about Retinal Degeneration (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 10 narrower conditions too, such as Macular Degeneration: 2,641 studies, 413 open.
Get an email when these change. Save the Retinal Degeneration studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Beacon Therapeutics (7) · Nanoscope Therapeutics Inc. (7) · Kodiak Sciences Inc (7) · National Eye Institute (NEI) (5) · Gyroscope Therapeutics Limited (5) · Novartis Pharmaceuticals (4) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (4) · Gemini Therapeutics, Inc. (3)
What is being tested here
Drugs under test in Retinal Degeneration studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Dapagliflozin | 1 | 0 | 1 |
| Minocycline | 1 | 0 | 1 |
| Tarcocimab tedromer | 0 | 6 | 6 |
| Ranibizumab | 0 | 1 | 4 |
| Aflibercept | 0 | 2 | 3 |
| Brolucizumab | 0 | 2 | 3 |
| Lusacomfar alfa | 0 | 0 | 3 |
| Gt-005 | 0 | 0 | 3 |
| VP-001 | 0 | 0 | 2 |
| RN-6G | 0 | 0 | 2 |
Drug classes tested here Angiogenesis inhibitors 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD · Phase 3 · AbbVie
- Feb 2027Promising ROd-cone DYstrophy Gene therapY · SparingVision
- Feb 2027First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration · Axovia Therapeutics
- Mar 2027Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa · University Hospital Tuebingen
- Mar 2027Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab · Johns Hopkins University
- Mar 2027Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance · Okuvision GmbH
- May 2027Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study · Nanoscope Therapeutics Inc.
- Jun 2027Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F · Jaeb Center for Health Research
- Jul 2027Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study · Nanoscope Therapeutics Inc.
- Jul 2027High Resolution, High-speed Multimodal Ophthalmic Imaging · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Who these studies take
Of the 15 Retinal Degeneration studies recruiting now, 10 (67%) set no upper age limit and 3 (20%) stop at 75 or younger. 7 (47%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 7 (47%) | 7 (47%) |
| 18 | 12 (80%) | 12 (80%) |
| 30 | 13 (87%) | 13 (87%) |
| 40 | 13 (87%) | 13 (87%) |
| 50 | 14 (93%) | 14 (93%) |
| 65 | 13 (87%) | 13 (87%) |
| 75 | 12 (80%) | 12 (80%) |
| 85 | 12 (80%) | 12 (80%) |
Across all 132 studies, recruiting or not: 15% stop at 75 or younger and 10% at 65; 26% take children; 0% are for women only and 8% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 132. Browse all 132 → or search them.
- Cell Collection to Study Eye DiseasesRecruitingNCT014328471 country
- Rod and Cone Mediated Function in Retinal DiseaseRecruitingNCT026179661 country
- Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and AdolescentsRecruitingNCT079019073 countries
- A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)RecruitingNCT06789445Phase 1/21 country
- Retinal and Choroidal Changes in Periodontal DiseaseNot yet recruitingNCT078569011 country
- ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent StudyEnrolling by invitationNCT05481827Phase 26 countries
- Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone DystrophyRecruitingNCT07807111Phase 1/23 countries
- Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)RecruitingNCT07002398Phase 1/21 country
- SGLT2 Inhibitors in Geographic AtrophyRecruitingNCT07174687Phase 21 country
- First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal DegenerationRecruitingNCT07269665Early Phase 11 country
- Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking OfatumumabEnrolling by invitationNCT061676421 country
- Adaptive Optics Imaging of Outer Retinal DiseasesRecruitingNCT053554151 country
- High Resolution Retinal ImagingRecruitingNCT018663711 country
- Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual PerformanceRecruitingNCT075489441 country
- Multicenter Study of Transcranial Magnetic Stimulation on Vision RestorationNot yet recruitingNCT07425717Not applicable1 country
- Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated PatientsRecruitingNCT05616793Phase 1/21 country
- Inherited Retinal Diseases: Natural History and Genotype-Phenotype CorrelationsNot yet recruitingNCT072658951 country
- High Resolution, High-speed Multimodal Ophthalmic ImagingRecruitingNCT04129021Not applicable1 country
- A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal InjectionEnrolling by invitationNCT059211621 country
- A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)Enrolling by invitationNCT06275620Phase 21 country
- Biomarkers in Retinitis PigmentosaRecruitingNCT063066901 country
- Validation of Questionnaire in Retinal DegenerationNot yet recruitingNCT06185517Not applicable
- Minocycline for Chronic Autoimmune UveitisRecruitingNCT05474729Phase 1/21 country
- Natural History of Eye Diseases Related to ABCA4 MutationsActive, not recruitingNCT017362931 country
- Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked RetinoschisisActive, not recruitingNCT06289452Early Phase 11 country
- Investigating Geographic Atrophy Insights (i-GAIN) Natural History StudyCompletedNCT057978962 countries
- Aflibercept After Ranibizumab in Exudative Age-related Macular DegenerationCompletedNCT02157077Phase 31 country
- Intravitreal Adalimumab in Inherited and Degenerative Retinal DiseasesActive, not recruitingNCT07348588Phase 1/21 country
- Oral Metformin for Treatment of ABCA4 RetinopathyActive, not recruitingNCT04545736Phase 1/21 country
- A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular EdemaCompletedNCT06305416Phase 31 country
- NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular DegenerationActive, not recruitingNCT05984927Phase 1/22 countries
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 310 countries
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaActive, not recruitingNCT07174726Phase 21 country
- MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)CompletedNCT06455826Phase 11 country
- A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001Active, not recruitingNCT06852963Phase 1/21 country
- Promising ROd-cone DYstrophy Gene therapYActive, not recruitingNCT05748873Phase 1/22 countries
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)CompletedNCT06270836Phase 32 countries
- Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis PigmentosaActive, not recruitingNCT063237721 country
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/31 country
- A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPActive, not recruitingNCT04850118Phase 2/34 countries
- Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis PigmentosaActive, not recruitingNCT03326336Phase 1/23 countries
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active, not recruitingNCT046452121 country
- Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1FActive, not recruitingNCT047653458 countries
- FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMDTerminatedNCT03846193Phase 1/22 countries
- HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005TerminatedNCT04566445Phase 27 countries
- EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005TerminatedNCT04437368Phase 28 countries
- Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B GeneTerminatedNCT03328130Phase 1/21 country
- Bridging Animal and Human Models of Exercise-induced Visual RehabilitationActive, not recruitingNCT02911805Not applicable1 country
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 42 countries
- Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular EdemaCompletedNCT05697809Phase 22 countries